Entera Bio Ltd.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Entera Bio Ltd. is a clinical-stage biopharmaceutical company specializing in the development and commercialization of orally delivered large molecule therapeutics targeting unmet medical needs. The company’s core products include oral peptide and protein replacement therapies primarily based on its proprietary N-Tab platform, which enhances the stabilization and systemic absorption of peptides in the gastrointestinal tract. Key product candidates include EB613 and EB612, oral formulations of human parathyroid hormone (PTH 1-34) designed for the treatment of osteoporosis and hypoparathyroidism, respectively. Entera is also developing the first oral oxyntomodulin tablet for obesity treatment and an oral GLP-2 peptide tablet for rare malabsorption conditions like short bowel syndrome, in collaboration with OPKO Biologics. The company’s products focus on transforming therapies traditionally administered by injection into convenient once-daily oral tablets to improve patient adherence and outcomes. Entera Bio operates globally with headquarters in Jerusalem, Israel, and addresses chronic conditions with significant unmet medical demand in metabolic bone disease, endocrine disorders, obesity, and intestinal malabsorption. Founded in 2012, the company is driven by a team of industry experts in drug development and oral peptide delivery. Recent major developments include a strategic research collaboration with OPKO Biologics initiated in 2023 to develop oral peptide tablet formulations for obesity and intestinal malabsorption, leveraging OPKO’s proprietary long-acting peptides and Entera’s oral delivery technology. Throughout 2025, Entera has reported positive clinical data supporting its oral GLP-2 treatment for short bowel syndrome and EB613 for osteoporosis, highlighting progress in its development pipeline for oral peptide therapeutics. The company also attracted increased investment interest with a notable acquisition of shares by Knoll Capital Management in late 2024, reflecting growing confidence in its clinical and technological prospects. Entera Bio maintains a strong intellectual property position with numerous patents and pending applications related to its oral delivery platform and peptide formulations. Its business model focuses on innovative oral therapies to replace injectable treatments, targeting cost, convenience, and compliance challenges in healthcare. The company’s advances embody a strategic shift towards delivering first-in-class oral peptide therapeutics aimed at improving the standard of care for chronic diseases that conventionally rely on injectable biologics. This comprehensive profile outlines Entera Bio’s specialized biopharmaceutical activities, advanced product pipeline, recent strategic collaborations, and clinical progress as of late 2025. The company remains headquartered in Jerusalem, Israel, serving a global market with products designed to enhance patient quality of life through oral peptide therapeutic innovation.
Entera's EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation
Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs
Entera Bio (ENTX) Upgraded to Buy: Here's What You Should Know
Entera Bio Ltd. (ENTX) Discusses Osteoporosis Treatment Landscape and Clinical Potential of EB613 Oral Tablet Transcript
BriefCast Publishes Transcript: Entera Bio's Osteoporosis KOL Roundtable on EB613 - Oral Anabolic Tablet Opportunity
Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613
Greenberg Traurig Represents Israel-based Entera Bio in $10M Private Placement Led by BVF Partners
Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds
Stock Market Today: S&P 500, Dow, Nasdaq Futures Gain As Trump Calls Iran's New Leaders 'Very Reasonable'— PLTR, RZLV, ENTX In Focus (UPDATED)
Stock Market Today: S&P 500, Dow Futures Gain As Trump Calls Iran's New Leaders 'Very Reasonable'—Palantir, Rezolve AI, Entera Bio In Focus
Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates
Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis
What Pushed Entera Bio (ENTX) To Rally Nearly 16% After Hours
Entera Bio Announces Open Market Purchases of Company Stock by Board Members
Entera Bio Appoints Former Pfizer Executive Geno J. Germano as Chairman of the Board Ahead of Key Milestones
OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism
Entera Bio Announces Upcoming Q1 2026 Corporate Priorities and Pipeline Outlook
Entera Bio Congratulates the FNIH-ASBMR-SABRE Team on FDA's Qualification of Total Hip BMD as Regulatory Endpoint: Huge Win for Osteoporosis Innovation
Entera Bio Announces New Data Supporting Further Development of a Proprietary First-in-Class Oral, Long-Acting PTH Tablet for Patients with Hypoparathyroidism (EB612 Program)
Entera Bio to Participate in the 8th Annual Evercore ISI Healthcare Conference